Japan determines the cost-effectiveness of medical devices through Health Technology Assessment (HTA), overseen by MHLW & Chuikyo. Manufacturers submit clinical & economic evidence, including cost-benefit analyses & quality-adjusted life years (QALYs). Devices are evaluated for their impact on healthcare outcomes & costs, ensuring alignment with NHI reimbursement criteria & system sustainability.
